爱游戏平台注册登录
check quantity

PD-L1 (human) AlphaLISA Detection Kit, 100 assay points

The AlphaLISA® Human PD-L1 Detection Kit is designed for detection and quantitation of human Programmed death ligand 1 (PD-L1; CD274/B7-H1) in cell culture media or serum using a homogeneous (no-wash steps, no separation steps) assay.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
AL355HV
100 assay points
1042.00 USD
 
more
AL355C
500 assay points
2214.00 USD
 
more
AL355F
5,000 assay points
14600.00 USD
 
more
爱游戏平台注册登录 Life Sciences & Diagnostics is now Revvity, but at this time, there is no change to the supplier information.
Request Technical Support

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Formats:

  • Our HV (100 assay point) kits allow you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. Human PD-L1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. PD-L1, together with PD-L2, are two ligands for PD-1 (programmed death 1), a member of the CD28 family of immunoreceptors. By binding to PD-1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Assay Target PD-L1
Assay Target Class Protein
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Format Microplates
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Oncology
Unit Size 100 assay points
Resources, Events & More
  • All

Application Note

Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA

Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more da ...

PDF 4 MB
Quantifying Changes in CD28 and CTLA-4 Levels in Peripheral Blood Mononuclear Cells with AlphaLISA Technology

One approach to immunotherapy is the modulation of immune checkpoints that are critical in regulating the degree and duration of immune system responses and preventing autoimmunity.

In this application note, you will learn:

  • Why AlphaLISA® technology is an effective assay for the ...

PDF 1 MB
Rapid, No-wash Measurement of Immune Checkpoint Molecules and Cytokines in Co-cultures of Immune Cells and Cancer Cell Lines

Breast cancer tumors can adapt to immune cell infiltration by responding to the increased concentration of interferon gamma (IFN-ɣ) and other cytokines secreted by subsets of T lymphocytes with the upregulation of the immune checkpoint proteins such as Programmed cell death ligand 1 (PD-L1). ...

PDF 2 MB
Soluble PD-L1 Detection in Cellular Supernatants Using AlphaLISA

When PD-1, which is expressed on the T cell, binds to PD-L1 expressed on the tumor cell, the T cell response is suppressed. Utilization of this pathway leads to tumor immune escape and promotes tumor cell growth. In fact, PD-L1 expression increases with tumor severity in many types of cancer. Rel ...

PDF 2 MB
Using AlphaLISA Biomarker Kits to Assess Effects of PBMC-Conditioned Media on 3D and 2D Cell Culture Models of Breast Cancer

Various cytokines are secreted during an active immune response that can have modulatory effects on target cell populations, including interferon gamma (IFN-ɣ), tumor necrosis factor alpha (TNFa) and several interleukins.

In this application note, you will learn how we investigated:

PDF 2 MB
Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint

Immune checkpoints serve a critical role in the immune system to prevent autoimmunity and manage the degree and duration of an immune response. Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4 or CD152) is an inhibitory transmembrane protein involved in an immune checkpoint of significant inte ...

PDF 1 MB

Brochure

Data Sheet

Flyer

Baidu
map